In breast cancer, preclinical studies have demonstrated sensitivity of HER2+ tumors to HSP90 inhibitor [2-4], lately though it was demonstrated that HSP90 is a very effective target of therapy in triple negative breast cancers [5,6]. This evidence concerns the gene HSP90AA1 and triple-negative breast carcinoma.